MDX has traversed a difficult path during the research and development process.
President-elect Donald Trump went after the pharmaceutical industry in the opening remarks of his first press conference since the election.
The Cambridge, Massachusetts-based biotech company has kept its pipeline a secret until now.
Japanese drugmaker Takeda acquired Boston-based Ariad Pharmaceuticals, a biotech company specializing in cancer drugs.
The biotech startup wants to use this new funding to advance development of its specialized early detection cancer test.
The Foster City, California-based biotech added a top cancer specialist to its executive ranks.
An analysis published by Deloitte’s Centre for Health Solutions indicated the pharmaceutical industry experienced a continued decline in R&D returns for...
Other researchers have used similar methods to sift through large amounts of data in order to pinpoint promising compounds to treat diseases.
These articles provide a snapshot of the change the pharmaceutical industry experienced throughout the year.
A new report explains how hospitals are implementing aggressive new measures to cut pharmaceutical spending in the face of rapidly rising prices for certain...
Novartis is bolstering its dermatology portfolio with a new acquisition.
Voyager Therapeutics is testing an experimental gene therapy that could boost Parkinson’s patients’ responses to levodopa.
Eli Lilly will launch a new program in conjunction with Express Scripts to offer diabetes patients lower prices for its insulin products.
Bayer in conjunction with Versant Ventures are investing up to $225 million in a startup called Bluerock Therapeutics in one of the largest Series A funding...
Biogen reported more encouraging data for its experimental Alzheimer’s treatment aducanumab on Thursday.
The transition team for President-elect Donald Trump is reportedly exploring an unusual pick to run the Food and Drug Administration.
Part of this restructuring process will include cutting less than 10 percent of its global workforce.
Heather Bresch came to the fifth annual Forbes Healthcare conference to talk about the fallout from the EpiPen pricing controversy.
This condition produces mutations that lead to a serious shortage of white blood cells.
Approximately 400,000 people all over the world are living with either hemophilia A or hemophilia B.
An experimental Alzheimer’s drug being developed by Eli Lilly failed to slow cognitive decline in patients with even a mild form of the condition.
Novartis is boosting its hematology pipeline with a new acquisition.
Amgen and Novartis are one step closer to having a contender in the migraine treatment space.
Amgen announced good news for its cholesterol drug Repatha at the annual American Heart Association meeting taking place in New Orleans.
Drug makers are working with companies like Propeller Health on these devices because they could provide improved adherence and better health outcomes.
The biotech company will pay $100 million upfront to Japan’s Nitto Denko who developed this drug.
Roche’s cancer drug business could soon face some competition.
Currently, there are no approved drugs for spinal muscular atrophy.
Nestle’s health science unit is expanding its presence in the biotech space with a new investment.
One of the world’s largest food and beverage companies is launching a new initiative to help children all over the world.
This endeavor could solve a difficult problem associated with drug development.
The new financing will be used to advance the firm’s cellular senescence research programs and commence clinical research.
The Auvi-Q injector is making a comeback.
A new study exonerates Gaetan Dugas, a French-Canadian flight attendant long considered to be “Patient Zero” in the 1980’s AIDS epidemic in the U.S.
GlaxoSmithKline is preparing to challenge Merck for control over the shingles vaccine market.
Alkermes saw its shares surge on Thursday after releasing new trial data related to its experimental drug to treat major depressive disorder, ALKS 5461.
The biotech company announced new study results on Thursday for two experimental therapies.
The funding will be allocated to a mix of academic institutions and private companies.
The drug maker initiated a series of wholesale price increases for therapies in three portfolios.